PreHevbrio
Selected indexed studies
- PreHevbrio: the first approved 3-antigen hepatitis B vaccine. (Expert Rev Vaccines, 2023) [PMID:37877189]
- A three-antigen hepatitis B vaccine (PreHevbrio). (Med Lett Drugs Ther, 2022) [PMID:35536120]
- PreHevbrio: A New 3-Antigen Hepatitis B Vaccine for Adults. (Ann Pharmacother, 2023) [PMID:35906803]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Adult immunization. (2022) pubmed
- PreHevbrio: the first approved 3-antigen hepatitis B vaccine. (2023) pubmed
- A three-antigen hepatitis B vaccine (PreHevbrio). (2022) pubmed
- PreHevbrio: A New 3-Antigen Hepatitis B Vaccine for Adults. (2023) pubmed
- The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen hepatitis B vaccine. (2023) pubmed
- Longterm Outcome of Therapeutic Vaccination with a Third Generation Pre-S/S HBV Vaccine (PreHevbrio(R)) of Chronically HBV Infected Patients. (2024) pubmed
- The role of new hepatitis B vaccines in South Africa. (2024) pubmed
- Optimal Timing of Delivery for Pregnant Individuals With Mild Chronic Hypertension. (2024) pubmed
- Cost-effectiveness of a 3-antigen versus single-antigen vaccine for the prevention of hepatitis B in adults in the United States. (2023) pubmed
- A three antigen hepatitis B vaccine induces T cells to Pres1 and Pres2 which correlate with anti HBs antibody titers: An investigation into the immunological mechanisms contributing to high anti-HBs titers. (2025) pubmed